Hinge Health Inc. $HNGE Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Key Points

• Zurcher Kantonalbank boosted its stake in Hinge Health by 755.1% in Q4, now owning 27,354 shares after acquiring an additional 24,155 shares, with holdings valued at about $1.27 million.
• Hinge Health reported a Q4 $0.49 EPS (vs. $0.04 expected) and revenue of $170.73 million (vs. $157.31 million), with revenue up 45.5% year-over-year.
• Significant insider selling occurred recently: CEO Daniel Antonio Perez sold 166,665 shares (~$6.71M) and insiders have sold a total of 442,670 shares valued at roughly $18.79 million in the last 90 days.

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Hinge Health Inc. (NYSE:HNGE - Free Report) by 755.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 27,354 shares of the company's stock after acquiring an additional 24,155 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Hinge Health were worth $1,271,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HNGE. First Horizon Corp increased its stake in Hinge Health by 163.9% during the 4th quarter. First Horizon Corp now owns 855 shares of the company's stock worth $40,000 after buying an additional 531 shares during the period. Sandler Capital Management increased its stake in Hinge Health by 1.4% during the 3rd quarter. Sandler Capital Management now owns 52,728 shares of the company's stock worth $2,588,000 after buying an additional 728 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Hinge Health during the 3rd quarter worth approximately $37,000. Jones Financial Companies Lllp increased its stake in Hinge Health by 348.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,120 shares of the company's stock worth $54,000 after buying an additional 870 shares during the period. Finally, Aster Capital Management DIFC Ltd purchased a new stake in Hinge Health during the 3rd quarter worth approximately $49,000.

Hinge Health Trading Down 1.7%

Shares of NYSE:HNGE opened at $43.96 on Thursday. Hinge Health Inc. has a 52 week low of $30.08 and a 52 week high of $62.18. The company's 50 day moving average is $41.98 and its two-hundred day moving average is $44.03. The company has a market cap of $3.46 billion and a PE ratio of -3.43.

Hinge Health (NYSE:HNGE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The company reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.45. The firm had revenue of $170.73 million during the quarter, compared to analysts' expectations of $157.31 million. Hinge Health's revenue was up 45.5% on a year-over-year basis. As a group, equities research analysts expect that Hinge Health Inc. will post 0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus set a $59.00 target price on shares of Hinge Health in a research note on Thursday, February 5th. Piper Sandler cut their target price on shares of Hinge Health from $71.00 to $60.00 and set an "overweight" rating on the stock in a research note on Friday, January 9th. Wells Fargo & Company assumed coverage on shares of Hinge Health in a research note on Thursday, January 8th. They set an "overweight" rating and a $68.00 target price on the stock. Canaccord Genuity Group cut their target price on shares of Hinge Health from $65.00 to $53.00 and set a "buy" rating on the stock in a research note on Wednesday, February 11th. Finally, KeyCorp set a $55.00 target price on shares of Hinge Health in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Hinge Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.73.

Insider Activity

In other Hinge Health news, CEO Daniel Antonio Perez sold 166,665 shares of the stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $40.26, for a total value of $6,709,932.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Gabriel M.I. Mecklenburg sold 33,333 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $45.05, for a total transaction of $1,501,651.65. Following the completion of the sale, the chairman directly owned 33,333 shares in the company, valued at approximately $1,501,651.65. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 442,670 shares of company stock valued at $18,786,901.

About Hinge Health

Hinge Health NYSE: HNGE is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company's platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.

Want to see what other hedge funds are holding HNGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hinge Health Inc. (NYSE:HNGE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.